The indications for H. pylori eradication therapy are as follows: 1, peptic ulcer (gastric ulcer, duodenal ulcer): is the most important indication for Hp eradication, eradication of Hp can promote ulcer healing, significantly reduce the rate of ulcer recurrence and complications. Hp eradication makes most peptic ulcers no longer a chronic, recurrent disease, but completely curable; 2. Gastric lymphoma: It is a rare malignant tumor of the stomach, about 80% of which are Hp-positive, and early stage (lesions limited to the mucosal layer or submucosal layer) gastric lymphoma can obtain a complete response after Hp eradication, but the efficacy is reduced if the lesion depth exceeds the submucosal layer. Hp eradication has become the first-line treatment for Hp-positive early gastric lymphoma; (2012 expert guidelines strongly recommend the above two conditions: Hp eradication) 3. Hp-positive chronic gastritis with dyspepsia: Hp eradication can provide long-term relief in 8% to 20% of Hp-positive FD patients, and this efficacy is better than any other treatment; 4. Chronic gastritis with gastric mucosal atrophy or erosion: Hp infection in <1% of people Atrophy and intestinalization are important lesion stages in the evolution from non-atrophic gastritis to gastric cancer. Atrophy and intestinal chemosis can occur after recurrent erosion. Although the best time to eradicate Hp to prevent gastric cancer is before the occurrence of atrophy and intestinal chemosis, Hp eradication at this stage can still eliminate the inflammatory response, slow down or stop the development of atrophy, and possibly reverse some of the atrophy, but intestinal chemosis is difficult to reverse; 5, early gastric tumors have been endoscopically resected or surgical gastric subtotal resection; 6, those who need to take proton pump inhibitors for a long time: Hp-infected patients taking PPI for a long time can change the type of gastritis. The type of gastritis can be changed from sinus-based gastritis to gastric body-based gastritis. This is because the pH in the stomach rises after taking PPI, which facilitates the displacement of Hp from the gastric sinus to the gastric body, and the inflammation and atrophy of the gastric body further reduces gastric acid secretion. The risk of gastric cancer is significantly higher in gastric body atrophy-based low or acid-free gastritis; 7. Family history of gastric cancer: Except for a few (about 1% to 3%) hereditary diffuse gastric cancers, the majority of gastric cancers occur as a result of the combined effect of Hp infection, environmental factors and genetic factors. Although it is difficult to change the genetic susceptibility, Hp eradication can eliminate important factors for the development of gastric cancer and thus improve the prevention effect; 8. Hp eradication increases hemoglobin levels, and Hp eradication increases platelet counts in more than 50% of patients with idiopathic thrombocytopenic purpura; 10. Individuals request treatment: conditions and benefits vary and should be critically evaluated by a physician prior to treatment. Hp eradication is supported for those aged <45 years and without alarming symptoms, but endoscopy is needed first for those aged >45 years or with alarming symptoms. The potential risks of this management strategy, including missed upper gastrointestinal cancers, masking, and adverse drug reactions, need to be clearly explained to the patient before treatment. (3 to 10) The 2012 expert guidelines recommend Hp eradication.